Screening MT1-MMP Activity and Inhibition in Three-Dimensional Tumor Spheroids.

FRET assay cell-based high-throughput screening collagen glioblastoma membrane type 1 matrix metalloproteinase spheroid triple helix

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
15 Feb 2023
Historique:
received: 27 08 2022
revised: 17 01 2023
accepted: 30 01 2023
entrez: 25 2 2023
pubmed: 26 2 2023
medline: 26 2 2023
Statut: epublish

Résumé

Membrane type 1 matrix metalloproteinase (MT1-MMP) has been shown to be crucial for tumor angiogenesis, invasion, and metastasis, and thus MT1-MMP is a high priority target for potential cancer therapies. To properly evaluate MT1-MMP inhibitors, a screening protocol is desired by which enzyme activity can be quantified in a tumor microenvironment-like model system. In the present study, we applied a fluorogenic, collagen model triple-helical substrate to quantify MT1-MMP activity for tumor spheroids embedded in a collagen hydrogel. The substrate was designed to be MT1-MMP selective and to possess fluorescent properties compatible with cell-based assays. The proteolysis of the substrate correlated to glioma spheroid invasion. In turn, the application of either small molecule or protein-based MMP inhibitors reduced proteolytic activity and glioma spheroid invasion. The presence of MT1-MMP in glioma spheroids was confirmed by western blotting. Thus, spheroid invasion was dependent on MT1-MMP activity, and inhibitors of MT1-MMP and invasion could be conveniently screened in a high-throughput format. The combination of the fluorogenic, triple-helical substrate, the three-dimensional tumor spheroids embedded in collagen, and Hit-Pick software resulted in an easily adaptable in vivo-like tumor microenvironment for rapidly processing inhibitor potential for anti-cancer use.

Identifiants

pubmed: 36831098
pii: biomedicines11020562
doi: 10.3390/biomedicines11020562
pmc: PMC9953393
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : James and Esther King Biomedical Research Program
ID : 8JK01

Références

Nat Rev Drug Discov. 2014 Dec;13(12):904-27
pubmed: 25376097
Biochim Biophys Acta Mol Basis Dis. 2022 Nov 1;1868(11):166522
pubmed: 35981653
Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12530-5
pubmed: 19617536
Curr Pharm Des. 2007;13(17):1787-802
pubmed: 17584108
Pharmacol Res. 2021 Sep;171:105780
pubmed: 34302977
J Neurooncol. 2011 Aug;104(1):33-43
pubmed: 21088866
J Korean Med Sci. 2000 Jun;15(3):309-14
pubmed: 10895974
Cancers (Basel). 2020 Aug 29;12(9):
pubmed: 32872536
Cancers (Basel). 2014 Feb 17;6(1):416-35
pubmed: 24549119
Biopolymers. 2013 Jul;100(4):347-55
pubmed: 23444261
Chem Biol Drug Des. 2019 Jun;93(6):1251-1264
pubmed: 30480376
Mol Pharm. 2014 Apr 7;11(4):1294-300
pubmed: 24641451
Mol Immunol. 1980 Jun;17(6):741-8
pubmed: 7432351
Small. 2014 Feb 12;10(3):566-75, 417
pubmed: 24038954
Exp Cell Res. 2014 Feb 15;321(2):99-108
pubmed: 24355810
Nat Rev Mol Cell Biol. 2006 Mar;7(3):211-24
pubmed: 16496023
Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):14970-14975
pubmed: 27965386
Adv Mater. 2015 Mar 4;27(9):1567-72
pubmed: 25521283
Cancer Res. 2016 Apr 15;76(8):2465-77
pubmed: 26896279
Mol Imaging. 2017 Jan-Dec;16:1536012117730950
pubmed: 28929923
Oncogenesis. 2016 Jun 06;5(6):e231
pubmed: 27270613
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Res. 1996 Jan 15;56(2):384-92
pubmed: 8542596
Front Pharmacol. 2016 Dec 07;7:477
pubmed: 28003805
Science. 2018 Mar 30;359(6383):1537-1542
pubmed: 29599246
Nature. 1994 Jul 7;370(6484):61-5
pubmed: 8015608
Cancer Res. 2010 Mar 15;70(6):2204-12
pubmed: 20197470
Cancer Cell. 2021 Apr 12;39(4):509-528.e20
pubmed: 33577785
PLoS One. 2012;7(2):e32269
pubmed: 22359676
Adv Exp Med Biol. 2016;923:413-419
pubmed: 27526171
J Biol Chem. 2002 Oct 11;277(41):39005-14
pubmed: 12145314
Adv Drug Deliv Rev. 2014 Dec 15;79-80:172-83
pubmed: 25174308
Mol Cancer Ther. 2005 May;4(5):751-60
pubmed: 15897239
J Biol Chem. 2008 Jun 20;283(25):17740-8
pubmed: 18441011
Cancer Res. 2012 May 1;72(9):2339-49
pubmed: 22406620
Biomaterials. 2013 Oct;34(30):7408-17
pubmed: 23827186
Cell. 2022 Jun 9;185(12):2184-2199.e16
pubmed: 35649412
Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1412-1426
pubmed: 31773232
Med Oncol. 2011 Dec;28 Suppl 1:S433-8
pubmed: 20809186
Nat Commun. 2019 Oct 4;10(1):4529
pubmed: 31586101
FASEB J. 2002 Apr;16(6):555-64
pubmed: 11919158
J Biol Chem. 1996 Apr 12;271(15):9135-40
pubmed: 8621565
Cell. 2007 Aug 24;130(4):601-10
pubmed: 17719539
Mol Cancer Ther. 2017 Sep;16(9):1909-1921
pubmed: 28659432
Chem Biol. 2011 Mar 25;18(3):392-401
pubmed: 21439484
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
J Biol Chem. 1992 Aug 15;267(23):16396-402
pubmed: 1644824
Cancer Res. 2010 Sep 1;70(17):6902-12
pubmed: 20663911
Cell Chem Biol. 2018 Apr 19;25(4):370-379.e4
pubmed: 29396288
J Immunol. 2010 Apr 1;184(7):3346-50
pubmed: 20208009
PLoS One. 2013;8(3):e58569
pubmed: 23516511
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Clin Transl Oncol. 2013 Feb;15(2):139-45
pubmed: 22855183
Biochem Pharmacol. 2022 Jul;201:115095
pubmed: 35598808
Open Med (Wars). 2022 Mar 09;17(1):492-507
pubmed: 35350840
J Biol Chem. 2008 Dec 19;283(51):35410-8
pubmed: 18955496
Anal Chem. 2021 Jun 29;93(25):8739-8745
pubmed: 34114806
Mol Cancer Res. 2003 Mar;1(5):333-45
pubmed: 12651907
FEBS Lett. 1996 Sep 9;393(1):101-4
pubmed: 8804434
Biochemistry. 2004 Sep 14;43(36):11474-81
pubmed: 15350133
J Cell Physiol. 2006 Jan;206(1):1-8
pubmed: 15920734
Front Oncol. 2021 Sep 17;11:717606
pubmed: 34604053
Mol Pharm. 2011 Dec 5;8(6):2331-8
pubmed: 22014151
Biomaterials. 2013 Oct;34(30):7344-52
pubmed: 23830581
Prog Mol Biol Transl Sci. 2017;148:339-354
pubmed: 28662827
Mol Biol Cell. 2006 Dec;17(12):5390-9
pubmed: 17050733
Neuro Oncol. 2013 Nov;15 Suppl 2:ii1-56
pubmed: 24137015
J Neurooncol. 2001 Jun;53(2):213-35
pubmed: 11716072
Cancer Lett. 2003 May 8;194(1):1-11
pubmed: 12706853
Nat Med. 2015 Nov;21(11):1364-71
pubmed: 26501191
Cytotechnology. 1992;8(3):219-29
pubmed: 1368819
Curr Neurol Neurosci Rep. 2001 May;1(3):225-32
pubmed: 11898522
Nanotheranostics. 2019 Sep 17;3(4):299-310
pubmed: 31723547
FEBS Lett. 1997 Feb 3;402(2-3):181-4
pubmed: 9037191
Cell Rep. 2020 Jul 14;32(2):107897
pubmed: 32668248

Auteurs

Anna M Knapinska (AM)

Alphazyme, Jupiter, FL 33458, USA.
Institute for Human Health & Disease Intervention (I-HEALTH), Florida Atlantic University, Jupiter, FL 33458, USA.

Gary Drotleff (G)

Alphazyme, Jupiter, FL 33458, USA.
Institute for Human Health & Disease Intervention (I-HEALTH), Florida Atlantic University, Jupiter, FL 33458, USA.

Cedric Chai (C)

Institute for Human Health & Disease Intervention (I-HEALTH), Florida Atlantic University, Jupiter, FL 33458, USA.

Destiny Twohill (D)

Institute for Human Health & Disease Intervention (I-HEALTH), Florida Atlantic University, Jupiter, FL 33458, USA.

Alexa Ernce (A)

Institute for Human Health & Disease Intervention (I-HEALTH), Florida Atlantic University, Jupiter, FL 33458, USA.

Dorota Tokmina-Roszyk (D)

Institute for Human Health & Disease Intervention (I-HEALTH), Florida Atlantic University, Jupiter, FL 33458, USA.

Isabella Grande (I)

Institute for Human Health & Disease Intervention (I-HEALTH), Florida Atlantic University, Jupiter, FL 33458, USA.

Michelle Rodriguez (M)

Institute for Human Health & Disease Intervention (I-HEALTH), Florida Atlantic University, Jupiter, FL 33458, USA.

Brad Larson (B)

Agilent Technologies, Raleigh, NC 27606, USA.

Gregg B Fields (GB)

Institute for Human Health & Disease Intervention (I-HEALTH), Florida Atlantic University, Jupiter, FL 33458, USA.

Classifications MeSH